Recent publication of two papers concerning oral Feraccru/Accrufer treatment for iron deficiency.- Shield Therapeutics
EULAR 2020: Lilly shares new data for Olumiant in rheumatoid arthritis and systemic lupus erythematosus.
Phase IIIb/IV SPIRIT-H2H study of Taltz shows efficacy in psoriatic arthritis.- Eli Lilly
Zeposia met primary and secondary endpoints in TRUE NORTH Phase III study for adult patients with moderate to severe ulcerative colitis.- BMS
Myovant Sciences has submitted an NDA to the FDA for its once-daily relugolix for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.
Brilinta approved by FDA to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease .-AstraZeneca
SURE 2 phase III clinical trial of sulopenem fails to meet endpoint in complicated urinary tract infection.- Iterum Therapeutics
Phase II DESTINYLung01 trial positive for Enhertu/Enhurtu in HER2 mutant NSCLC.- Daiichi Sankyo and AstraZeneca.
VBL presents positive interim data from the OVAL phase III pivotal study of VB 111 in ovarian cancer at the ASCO meeting, showing 58% or higher objective response rate
Gilead announces results from phase III trial of remdesivir in patients with moderate COVID-19.- Gilead Sciences.
IDMC reports phase III PALLAS trial of Ibrutinib unlikely to meet endpoint in early breast cancer.- Pfizer
CHMP recommends approval of Lynparza for metastatic adenocarcinoma of the pancreas.- AstraZeneca
FDA approves Cyramza + erlotinib for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.- Eli Lilly
CHMP recommends approval of Hepcludex for chronic hepatitis delta virus.- Myr
CHMP recommends approval of Rozlytrek for ROS1-positive advanced non-small cell lung cancer.- Roche
CHMP recommends Zercepac for treating breast or gastric cancer.- Accord Healthcare
Phase III ASPEN trial of Brukinsa in Waldenström’s macroglobulinemia shows positive follow-up data.- BeiGene
CHMP recommends approval of Rozlytrek in NTRK fusion-positive solid tumours.- Roche
CHMP recommends approval of Xenleta for community-acquired pneumonia.- Nabriva Therapeutics
Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial .- AstraZeneca + Daiichi Sankyo.
Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial. - AstraZeneca
FDA approves Tecentriq + Avastin for people with unresectable or metastatic hepatocellular carcinoma . Genentech/Roche
Minerva Neurosciences announces results from phase III trial of roluperidone (MIN-101) for treatment of negative symptoms in schizophrenia.
Santhera provides update on the ongoing regulatory review of Puldysa by the CHMP in Duchenne Muscular Dystrophy.
FDA approves Zilxi for rosacea.- Menlo Therapeutics
Phase III HERO study of TAK 385 for prostate cancer published in New England Journal of Medicine.- Myovant Sciences
Piqray + fulvestrant receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation.- Novartis
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug
Long-term disease control in Psoriasis: announcing a new project
Senolytics: an emerging therapeutic for the prevention and treatment of cardiovascular disease
Targeted therapies in triple negative breast cancer
Targeted therapies in HER2 negative breast cancer
Targeted therapies in HER2 positive breast cancer
Breast Cancer- Targeted therapies
World Congress of Dermatology 2019 - A new ERA for global Dermatology
Opioids - Over the horizon
Opioids: The war on drugs
Opioids: the future and challenging the epidemic